JP2011520908A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520908A5
JP2011520908A5 JP2011509721A JP2011509721A JP2011520908A5 JP 2011520908 A5 JP2011520908 A5 JP 2011520908A5 JP 2011509721 A JP2011509721 A JP 2011509721A JP 2011509721 A JP2011509721 A JP 2011509721A JP 2011520908 A5 JP2011520908 A5 JP 2011520908A5
Authority
JP
Japan
Prior art keywords
phenyl
oxo
carboxamide
dihydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509721A
Other languages
English (en)
Japanese (ja)
Other versions
JP5699075B2 (ja
JP2011520908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044034 external-priority patent/WO2009140549A1/en
Publication of JP2011520908A publication Critical patent/JP2011520908A/ja
Publication of JP2011520908A5 publication Critical patent/JP2011520908A5/ja
Application granted granted Critical
Publication of JP5699075B2 publication Critical patent/JP5699075B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509721A 2008-05-14 2009-05-14 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ Expired - Fee Related JP5699075B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12775308P 2008-05-14 2008-05-14
US61/127,753 2008-05-14
PCT/US2009/044034 WO2009140549A1 (en) 2008-05-14 2009-05-14 Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2011520908A JP2011520908A (ja) 2011-07-21
JP2011520908A5 true JP2011520908A5 (OSRAM) 2012-06-14
JP5699075B2 JP5699075B2 (ja) 2015-04-08

Family

ID=40908799

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509721A Expired - Fee Related JP5699075B2 (ja) 2008-05-14 2009-05-14 癌の治療のためのvegf(r)阻害剤および肝細胞増殖因子(c−met)阻害剤との組合せ

Country Status (7)

Country Link
US (2) US20110104161A1 (OSRAM)
EP (1) EP2288383A1 (OSRAM)
JP (1) JP5699075B2 (OSRAM)
AU (1) AU2009246263B2 (OSRAM)
CA (1) CA2723617A1 (OSRAM)
MX (1) MX2010012290A (OSRAM)
WO (1) WO2009140549A1 (OSRAM)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
US20090053236A1 (en) 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
EP2065372B1 (en) 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2265270A1 (en) 2008-02-04 2010-12-29 OSI Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2010045344A1 (en) * 2008-10-17 2010-04-22 Genentech, Inc. Combination therapy comprising a c-met antagonist and a vegf antagonist
US8592448B2 (en) 2008-11-20 2013-11-26 OSI Pharmaceuticals, LLC Substituted pyrrolo[2,3-b]-pyridines and -pyrazines
US8293925B2 (en) 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
WO2011139891A1 (en) * 2010-04-29 2011-11-10 Deciphera Pharmaceuticals, Llc Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activites
JP2013526570A (ja) 2010-05-14 2013-06-24 オーエスアイ・ファーマシューティカルズ,エルエルシー 縮合二環式キナーゼ阻害剤
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
WO2012003338A1 (en) * 2010-07-01 2012-01-05 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20140057908A1 (en) * 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
EP2621481B2 (en) 2010-09-27 2022-10-19 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
WO2012044574A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012042421A1 (en) * 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JP5707518B2 (ja) 2011-02-28 2015-04-30 カリトル サイエンシズ, エルエルシー 置換型キノリン化合物及び使用方法
KR20120100027A (ko) * 2011-03-02 2012-09-12 한국생명공학연구원 엔도사이토시스 모티프 및 단백질 도입 도메인을 포함하는 암 예방 또는 치료용 약학적 조성물
CN103415514B (zh) 2011-03-29 2015-09-30 卫材R&D管理有限公司 用于生产苯氧基吡啶衍生物的方法
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2012275346B2 (en) * 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
KR20140064971A (ko) * 2011-09-19 2014-05-28 제넨테크, 인크. c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
WO2013151913A1 (en) * 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
HUE032306T2 (en) 2012-06-26 2017-09-28 Bayer Pharma AG N- [4- (quinolin-4-yloxy) cyclohexyl (methyl)] (hetero) arylcarboxamides as androgen receptor antagonists, their production and use as pharmaceutical products
EP2879677B1 (en) * 2012-07-28 2017-06-14 Calitor Sciences, LLC Substituted pyrazolone compounds and methods of use
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
CN108530458A (zh) 2013-11-01 2018-09-14 卡拉制药公司 治疗化合物的结晶形式及其用途
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
TW201622744A (zh) * 2014-03-04 2016-07-01 美國禮來大藥廠 癌症之組合療法
US20150299219A1 (en) * 2014-04-22 2015-10-22 Calitor Sciences, Llc Bicyclic pyrazolone compounds and methods of use
CN113683564A (zh) 2014-08-28 2021-11-23 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
JP6267619B2 (ja) * 2014-09-30 2018-01-24 学校法人近畿大学 慢性骨髄性白血病の治療用組成物
ES2749726T3 (es) * 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
WO2017083788A1 (en) * 2015-11-14 2017-05-18 Sunshine Lake Pharma Co., Ltd. Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
TWI781920B (zh) 2016-02-05 2022-11-01 美商戴納立製藥公司 化合物、組合物及方法
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
PL3552017T3 (pl) 2016-12-09 2022-08-08 Denali Therapeutics Inc. Związki użyteczne jako inhibitory RIPK1
MY196680A (en) 2017-01-26 2023-04-29 Ono Pharmaceutical Co Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2- pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3- quinolinecarboxamide
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
ES2991062T3 (es) 2017-02-15 2024-12-02 Taiho Pharmaceutical Co Ltd Composición farmacéutica
MX389244B (es) 2017-04-27 2025-03-20 Astrazeneca Ab Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
US12280045B2 (en) 2017-09-08 2025-04-22 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect potentiator
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Axl阻害剤を有効成分として含む固形がん治療剤
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
WO2021055350A1 (en) 2019-09-16 2021-03-25 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
BR112022019517A2 (pt) * 2020-03-30 2022-12-06 Hutchison Medipharma Ltd Compostos de amida e usos dos mesmos
US20230301972A1 (en) * 2020-05-20 2023-09-28 Fred Hutchinson Cancer Center Anti-fibrotic composition and related methods
BR112023021111A2 (pt) 2021-04-13 2023-12-19 Nuvalent Inc Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2
IL314082A (en) 2022-01-12 2024-09-01 Denali Therapeutics Inc Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide
CN117126142A (zh) * 2023-08-30 2023-11-28 遵义医科大学珠海校区 杂环类egfr突变抑制剂及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
DE102004035655A1 (de) * 2004-07-22 2006-02-16 Henkel Kgaa Verfahren zur Herstellung von Mehrphasen-Sticks für die WC-Reinigung
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
JO2787B1 (en) * 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
WO2007092178A1 (en) * 2006-02-10 2007-08-16 Amgen Inc. Hydrate forms of amg706
BRPI0709917A2 (pt) * 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Similar Documents

Publication Publication Date Title
JP2011520908A5 (OSRAM)
CA2605680A1 (en) Substituted amide derivatives as protein kinase inhibitors
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
JP2008521900A5 (OSRAM)
JPWO2020231808A5 (OSRAM)
CA2671744A1 (en) Compounds and compositions as protein kinase inhibitors
HRP20231730T1 (hr) Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
CA2587642A1 (en) Substituted heterocycles and methods of use
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2019504821A5 (OSRAM)
HRP20140265T1 (hr) Derivat aminopirazina i odgovarajuä†i lijek
MX2010012290A (es) Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
RU2014110172A (ru) Гетероциклическое производное и фармацевтическое средство
JP2014062093A5 (OSRAM)
JP2015500332A5 (OSRAM)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
SI3074386T1 (en) New aminopyrimidine derivatives
SI3177619T1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
JP2017530185A5 (OSRAM)
IL295076A (en) Piperidinone derivatives as mdm2 inhibitors for cancer therapy
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
RU2014131378A (ru) Ингибиторы бромдомена
JP2006520805A5 (OSRAM)
JP2009515814A5 (OSRAM)
HRP20221454T1 (hr) Piridinamin-piridonski i pirimidinamin-piridonski spojevi